Explore Business Standard
<b>Pharma majors take dose of R&D</b><br><br> Indian pharmaceutical companies continue to chase the new chemical entity (NCE) dream.<br><br> They have made a few breakthroughs in generics and novel drug delivery systems such as Ranbaxys once-a-day Ciprofloxacin. In the last two years, though, the top guns have devoted themselves to NCE development with encouraging results.<br><br> Apart from an anti-malaria molecule, Ranbaxy is developing two with GlaxoSmithKline and seven others on its own.<br><br>
<b>Pharma majors take dose of R&D</b><br><br> Indian pharmaceutical companies continue to chase the new chemical entity (NCE) dream.<br><br> They have made a few breakthroughs in generics and novel drug delivery systems such as Ranbaxys once-a-day Ciprofloxacin. In the last two years, though, the top guns have devoted themselves to NCE development with encouraging results.<br><br> Apart from an anti-malaria molecule, Ranbaxy is developing two with GlaxoSmithKline and seven others on its own.<br><br>